Archive. Year 2012
Ampio Pharmaceuticals Announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
11/28/2012 | Press Release
Ampio Provides Progress Report on Clinical Programs in Preparation for Annual Shareholders Meeting
11/14/2012 | Press Release
Ampio Provides Update of Manufacturing Plans for Zertane™
09/12/2012 | Press Release
Ampio Announces Successful Pre-IND Meeting with the Ophthalmology Division of the FDA on Optina™ for the Treatment of Diabetic Macular Edema
08/01/2012 | Press Release
Ampio Pharmaceuticals Announces Closing of Public Offering
07/18/2012 | Press Release
Ampio Advances NCE001 Cancer Drug into Preclinical Development Following Successful Recent Financing and the Granting of Patents in USA, Canada, Europe and China
07/16/2012 | Press Release
Ampio Pharmaceuticals Announces Exercise of Over-Allotment Option
07/13/2012 | Press Release
Ampio Pharmaceuticals Announces Proposed Public Offering
07/12/2012 | Press Release
Ampio Pharmaceuticals Announces Pricing of Public Offering of 4,615,400 Shares of Common Stock
07/12/2012 | Press Release
Highlights of significant results on Orally administered Optina™ for Diabetic Macular Edema (DME), including results for visual acuity.
07/09/2012 | Press Release
Ampio's CEO and CSO Send Message to Shareholders
07/03/2012 | Press Release
Ampio Contracts with Syngene to Manufacture Zertane-ED™, its Recently Patented Combination Drug to Treat both Premature Ejaculation (PE) and Erectile Dysfunction (ED)
07/02/2012 | Press Release
Ampio Reports Successful Type B Pre-IND Meeting with the FDA for its Drug Zertane™ to treat Premature Ejaculation (PE)
06/21/2012 | Press Release
Ampio Announces Positive Clinical Trial Results for the Treatment of Diabetic Macular Edema with Orally Administered Optina™
06/11/2012 | Press Release
Ampio Patent Protection for Optina™ Expands to Include Europe
05/31/2012 | Press Release
Ampio Pharmaceuticals Schedules 2012 Update Webcast
05/14/2012 | Press Release
Ampio Pharmaceuticals Reports Pre-IND Meeting With the FDA to Obtain Clinical Path Guidance for Ampion™ for the Treatment of Chronic Pain of Osteoarthritis of the Knee and Schedules May 16th Webcast to Update Shareholders
05/11/2012 | Press Release
Ampio Pharmaceuticals announces extended analysis of Ampion™ In the Knee (AIK) Study shows pain relief of osteoarthritis, 84 days after a single injection into the knee, is statistically significant
04/30/2012 | Press Release
Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
04/27/2012 | Press Release
Ampio Pharmaceuticals Announces Presentation at Imperial Capital 2012 Healthcare Investor Forum
04/16/2012 | Press Release
Ampio Completes Patient Enrollment for Its Oxidation Reduction Potential (ORP) Clinical Trials
04/12/2012 | Press Release
Ampio Submits Type B Pre IND Meeting Request to the FDA for Zertane™
04/09/2012 | Press Release
Ampio Reaches Agreement with the TGA for the Submission Plan for Zertane in Australia
04/02/2012 | Press Release
Ampio Pharmaceuticals Announces the Licensing of Zertane™ to FBM Industria Farmaceutica Ltda to Commercialize in Brazil
03/22/2012 | Press Release
Ampio Strengthens Patent Protection for Lead Drug Ampion™
03/20/2012 | Press Release
Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule
03/19/2012 | Press Release
Ampio Pharmaceuticals Announces Presentation at Cowen & Company 32nd Annual Health Care Conference
03/05/2012 | Press Release
Ampio Pharmaceuticals Reports Full-Year 2011 Financial Results and Milestone Highlights for 2011
02/09/2012 | Press Release
Ampio Pharmaceuticals, Inc. Announces Statistically Significant Improvement in Pain Relief for its Lead Product, Ampion™ in the Osteoarthritis of the Knee Trial
01/31/2012 | Press Release
Register Now For AMPIO’s January 26, 2012 Outlook Call
01/26/2012 | News
Ampio Pharmaceuticals' Zertane™ Patent Estate Bolstered by Two New European Patents
01/17/2012 | Press Release
Ampio Pharmaceuticals Schedules 2012 Outlook Webcast
01/17/2012 | Press Release
Executive Changes at Ampio
01/09/2012 | Press Release
Ampio Pharmaceuticals Schedules Webcast to Update Shareholders
01/05/2012 | Press Release
Ampio Pharmaceuticals Completes Expanded Patient Enrollment for Ampion™ In Osteoarthritis of the Knee Clinical Trial in Australia
01/03/2012 | Press Release
Years: 2013 | 2012 | 2011 | 2010
Learn More About:
Premature Ejaculation (PE)
Premature ejaculation is a distressing male sexual dysfunction that is more common than erectile dysfunction (ED) and has a major impact on the quality of life for men and their sexual partners.
Diabetic Retinopathy
A complication of diabetes mellitus that damages the retina in the eyes and leads to blindness
Diabetic Nephropathy
A progressive complication of diabetes mellitus that leads to end-stage renal disease (ESRD) requiring kidney transplantation or chronic dialysis
| AMPE Stock Quote - delayed | ||
| Last | Change | |
| AMPE | 6.10 | |
Ampio News
06/07/2013 | Press Release
Ampio Pharmaceuticals Issues Statement Regarding Misleading Blog
06/06/2013 | Press Release
Ampio Pharmaceuticals to List on the NYSE MKT
06/03/2013 | Press Release